MARC Mid-Atlantic Renal Coalition
300 Arboretum Place   Suite #310
Richmond, VA 23236
Phone: 804.320.0004
Fax: 804.320.5918
Patient Toll Free 866.651.6272
marc@nw5.esrd.net
HomeAbout UsClinicalDataEducationPatients & FamiliesNewsContact Us

Description of Network 5 Surgeon Data Analytic Methods

Medicare Part B Vascular Access Procedure Reports were prepared for all surgeons in the Network 5 region, which includes the District of Columbia, Maryland, Virginia and West Virginia. Each report is confidential and shared only with the surgeon performing the vascular access procedures reported therein. The surgeon is free to further distribute the report.  Click here to download a printable version of the analytic methods applied.

Methods

Data: Medicare Part B claims

Inclusion Criteria: Claims were included in the analytic file if they met all of the following,
  • Contained a procedure code found in Table 1;
  • Contained a diagnosis code found in Table 2;
  • Were for a service occurring on or between January 1, 2009 and December 31, 2010;
  • Were either paid or denied payment by CMS;
  • Were performed by a surgeon classified as a general, thoracic, or vascular surgeon in the 2009 or 2010 claims; for 2009, peripheral vascular disease and cardiac surgeons were also included;
  • Were submitted by a surgeon having a practice address in the District of Columbia, Maryland, Virginia or West Virginia, per the National Provider Identifier (NPI) Registry, as of January 2012; and
  • Were submitted by a surgeon who performed at least one vascular access placement procedure.

 

Table 1: Vascular Access Procedure Codes Used to Select Medicare Part B claims, 2009 and 2010

Healthcare Common Procedure Coding System (HCPCS) Procedure Description

 

Abbreviation

Access Placement
 
36818
Arteriovenous anastomosis, open; by upper arm cephalic vein transposition 
AVF
 
36819
 
AV fusion/uppr arm vein
AVF
 
36820
AV anastomosis, open, by forearm transposition
AVF
36821
AV fusion direct any site
AVF
36825
Creation of AVF, autogenous graft insertion
AVF
36830
Creation of AVF, non-autogenous graft insertion
AVG
36558
Frequently used tunneled catheter code
CVC
36565
Tesio type catheter for hemodialysis
CVC

Secondary Procedures

36831
Thrombectomy, open, arteriovenous fistula without revision, autogenous or nonautogenous dialysis graft (separate procedure)
 
36832
Revision of AVF without thrombectomy
 
36833
Revision, open, arteriovenous fistula; with thrombectomy, autogenous or nonautogenous dialysis graft (separate procedure)
 
36834
Plastic repair of arteriovenous aneurysm (separate procedure)
 
36870
Percutaneous AV access graft mechanical thrombectomy with or without instillation of thrombolytic
 
37607
Ligation or banding of angioaccess arteriovenous fistula
 
G0392
Angioplasty AVF arterio site
 
G0393
Angioplasty AVF venous end
 
35476
Repair venous blockage (venous angioplasty)
 
35903 Excision of infected graft-extremities; revision, removal, dic AV access stenosis-imaging and treatment  
36145 AV access catheterization  
36147 Introduction of needle and/or catheter, arteriovenous shunt created for dialysis (graft/fistula)  
75791 Angiography, AV shunt (e.g. dialysis patient fistula/graft)  

 

Table 2: ICD-9-CM Diagnosis Codes Used to Select Medicare Part B claims, 2009 and 2010

016.0   Tuberculosis of kidney
095.4   Syphilis of kidney)
189.0   Malignant neoplasm of kidney except pelvis
189.9   Malignant neoplasm of urinary organ site unspecified
223.0   Benign neoplasm of kidney and other urinary organs
236.91 Neoplasm of uncertain behavior of kidney and ureter
250.40 Diabetes mellitus with renal manifestations type ii or unspecified type not stated as uncontrolled
250.41 Diabetes mellitus with renal manifestations type i not stated as uncontrolled
250.42 Diabetes mellitus with renal manifestations type ii or unspecified type uncontrolled
250.43 Diabetes mellitus with renal manifestations type i uncontrolled
271.4   Renal glycosuria
274.1   Gouty nephropathy
283.11 Hemolytic-uremic syndrome
403.01 Malignant hypertensive renal disease with renal failure
403.11 Benign hypertensive renal disease with renal failure
403.91 Unspecified hypertensive renal disease with renal failure
404.02 Malignant hypertensive heart and renal disease with renal failure
404.03 Malignant hypertensive heart and renal disease with heart failure and renal failure
404.12 Benign hypertensive heart and renal disease with renal failure
404.13 Benign hypertensive heart and renal disease with heart failure and renal failure
404.92 Unspecified hypertensive heart and renal disease with renal failure
404.93 Unspecified hypertensive heart and renal disease with heart failure and renal failure
440.1   Atherosclerosis of renal artery
442.1   Aneurysm of renal artery
572.4   Hepatorenal syndrome
580.0   Acute glomerulonephritis with lesion of proliferative glomerulonephritis
580.4   Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis
580.81 Acute glomerulonephritis in diseases classified elsewhere
580.89 Acute glomerulonephritis with other specified pathological lesion in kidney
580.9   Acute glomerulonephritis with unspecified pathological lesion in kidney
581.0   Nephrotic syndrome with lesion of proliferative glomerulonephritis
581.1   Nephrotic syndrome with lesion of membranous glomerulonephritis
581.2   Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis
581.3   Nephrotic syndrome with lesion of minimal change glomerulonephritis
581.81 Nephrotic syndrome in diseases classified elsewhere
581.89 Other nephrotic syndrome with specified pathological lesion in kidney
581.9   Nephrotic syndrome with unspecified pathological lesion in kidney
582.0   Chronic glomerulonephritis with lesion of proliferative glomerulonephritis
582.1   Chronic glomerulonephritis with lesion of membranous glomerulonephritis
582.2   Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis
582.4   Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis
582.81 Chronic glomerulonephritis in diseases classified elsewhere
582.89 Other chronic glomerulonephritis with specified pathological lesion in kidney
582.9   Chronic glomerulonephritis with unspecified pathological lesion in kidney
583.0   Nephritis and nephropathy not specified as acute or chronic with lesion of proliferative glomerulonephritis
583.1   Nephritis and nephropathy not specified as acute or chronic with lesion of membranous glomerulonephritis
583.2   Nephritis and nephropathy not specified as acute or chronic with lesion of membranoproliferative glomerulonephritis
583.4   Nephritis and nephropathy not specified as acute or chronic with lesion of rapidly progressive glomerulonephritis
583.6   Nephritis and nephropathy not specified as acute or chronic with lesion of renal cortical necrosis
583.7   Nephritis and nephropathy not specified as acute or chronic with lesion of renal medullary necrosis
583.8   Nephritis and nephropathy not specified as acute or chronic with other specified pathological lesion in kidney
583.81 Nephritis and nephropathy not specified as acute or chronic in diseases classified elsewhere
583.89 Other nephritis and nephropathy not specified as acute or chronic with specified pathological lesion in kidney
583.9   Nephritis and nephropathy not specified as acute or chronic with unspecified pathological lesion in kidney
584.5   Acute kidney failure with lesion of tubular necrosis
584.6   Acute kidney failure with lesion of renal cortical necrosis
584.7   Acute kidney failure with lesion of medullary (papillary) necrosis
584.8   Acute kidney failure with other specified pathological lesion in kidney
584.9   Acute kidney failure, unspecified
585.2   Chronic kidney disease, stage ii (mild)
585.3   Chronic kidney disease, stage iii (moderate)
585.4   Chronic kidney disease, stage iv (severe)
585.5   Chronic kidney disease, stage v
585.6   End stage renal disease
585.9   Chronic kidney disease, unspecified
586      Renal failure unspecified
587      Renal sclerosis unspecified
588.0   Renal osteodystrophy
588.1   Nephrogenic diabetes insipidus
588.8   Other specified disorders resulting from impaired renal function
588.81 Secondary hyperparathyroidism (of renal origin)
588.89 Other specified disorders resulting from impaired renal function
588.9   Unspecified disorder resulting from impaired renal function
591      Hydronephrosis
753.12 Polycystic kidney unspecified type
753.13 Polycystic kidney autosomal dominant
753.14 Polycystic kidney autosomal recessive
753.15 Renal dysplasia
753.16 Medullary cystic kidney
753.17 Medullary sponge kidney
753.19 Other specified cystic kidney disease
753.20 Unspecified obstructive defect of renal pelvis and ureter
753.21 Congenital obstruction of ureteropelvic junction
753.22 Congenital obstruction of ureterovesical junction
753.23 Congenital ureterocele
753.29 Other obstructive defect of renal pelvis and ureter
794.4   Nonspecific abnormal results of function study of kidney


Definitions

Permanent vascular access placement patterns

The following measures are reported for the surgeon, the state, and the Network in 2009 and 2010; United States measures are for 2010 only. The Network region includes the District of Columbia, Maryland, Virginia and West Virginia.

AVF Total Placed is the count of vascular access placements that were arteriovenous fistulas.

AVF % is the percent of permanent vascular access placements that were arteriovenous fistulas. AVF % = (AVF Total Placed / (AVF Total Placed + AVG Total Placed)) * 100.

AVG Total Placed is the count of vascular access placements that were arteriovenous grafts.

AVG % is the percent of permanent vascular access placements that were arteriovenous grafts. AVG % = (AVG Total Placed / (AVF Total Placed + AVG Total Placed)) * 100.

Note: Column percentages in the Report sum to 100%. Any deviations from 100% are due to rounding. For example, a surgeon may have placed 20 AVFs and 10 AVGs. In this case, the AVF % = (20/(20+10))*100 = 66.7%; AVG % = 33.3%.  Summing: 66.7% + 33.3% = 100.0%.

Numbers of vascular access procedures

The following are reported for the surgeon, the state median, and the Network median in 2009 and 2010. 

Patients is the number of Medicare beneficiaries with kidney disease for whom Medicare Part B claims were submitted for either placement of a vascular access or secondary procedure, as given by the codes in Table 1.

AVF + AVG is the sum of the number of arteriovenous fistula and arteriovenous graft  placement procedures for which Medicare Part B claims were submitted.

Secondary is the number of secondary procedures, given by the codes in Table 1, for which Medicare Part B claims were submitted.  Included are thrombectomy, angioplasty, and other revisions of AVFs and AVGs.

CVC is the number of vascular access placements that were central venous catheters.


Important considerations

  • The Medicare Part B Vascular Access Procedure Reports were produced for surgeons in District of Columbia, Maryland, Virginia and West Virginia who submitted Medicare Part B claims as described through the inclusion criteria above. There were 312 surgeons in this geographic region meeting inclusion criteria in 2009 and 296 in 2010. The state, Network, and United States (in 2010 only) averages for AVF and AVG, as well as the state and Network medians for patients, AVF + AVG, secondary procedures and CVC were calculated from claims submitted by the 312 and 296 surgeons in the respective years. Reports were prepared for the 296 surgeons who performed placements in 2010.

  • The effectiveness of placed accesses cannot be ascertained with the claims data.
  • Whether a vascular access is the patient’s first, fourth, or sixth placement cannot be determined with the claims data.

  • Patients move or travel for services and may use more than one surgeon.  This is a surgeon driven analysis.  The data were divided using surgeon practice locations, not patient addresses.  CMS drew the 2009 claims data in 2010 and partitioned the data set per provider practice location at that time. Thereafter, CMS sent each Network data files for only those providers with practice locations within the Network’s geographic boundaries.  The same procedure was repeated with the 2010 claims. In the latter case, the data sets were constructed in 2011, partitioned per provider practice location in January 2012 and distributed to each Network, as was previously done. This means that a surgeon who moved his/her practice location from one Network geographic location to another within the relevant timeframe may not see his/her 2009 data in the Vascular Access Feedback Report produced by the Network. This happens because the data do not follow the surgeon.

  • The data may be used in combination with other data for internal quality improvement initiatives.

  •  


This website is
Section 508 Compliant.

Documents are presented in Adobe PDF; click here to download free Adobe Reader.

Powered by Kentico CMS